Announcement • May 08
Spermosens AB (publ) announced that it expects to receive SEK 4.85 million in funding Spermosens AB (publ) has announced a private placement to issue units at the price of 15% discount to VWAP for the gross proceeds of SEK 4,850,000 on May, 2026. The transaction involves the existing share holder investor participation and CEO Tore Duvold via Duvold Holding ApS for SEK 0.1 million Chairman Ulrik Spork for SEK 0.1 million Mount Nebo Investments LLC for SEK 2.0 million Seven additional shareholders for SEK 2.65 million combined. Each unit will consist of one share and one warrant issued free of charge. The warrants will have a term of three years and entitle the holder to subscribe for one new share at a subscription Exercise price of SEK 0.025 per share. The warrants may be exercised during one week prior to each half-year during the term. The transaction is approved by board of directors and subject to approval of shareholders at the AGM on June 18, 2026 for authorization to issue securities. Announcement • May 01
Spermosens AB Reports Clinical Validation Study of Juno-Checked Generation 3 System on Track Spermosens AB reported that the clinical validation study of the JUNO-Checked Generation 3 system at the Reproductive Medicine Center (RMC) in Malmö has started and is progressing according to plan. Seven patients have been successfully tested to date. The study started in April 2026, in line with the previously communicated timeline. The Company completed development of the Generation 3 system and planned to initiate patient recruitment at the RMC in Malmö. The study is now underway, and the first weeks confirm that patient recruitment and clinical routines are progressing as expected, with the JUNO-Checked Generation 3 system performing as intended. The study includes couples undergoing standard IVF treatment due to unexplained infertility, where semen samples show normal parameters based on currently available sperm analysis methods. Unlike standard semen analysis, JUNO-Checked measures whether sperm cells can bind to the egg, which is essential for fertilization. The aim of the study is to confirm that the Generation 3 system can identify the cause of fertilization failure in cases where standard testing shows no abnormalities. Completion of the study is expected by the end of 2026. Spermosens aims to bring JUNO-Checked to the global market through licensing or partnership agreements with established companies. Successful completion of the clinical validation study is a key step toward commercialization. Announcement • Apr 10
Spermosens AB Completes Development of JUNO-Checked Generation 3 and Initiates Clinical Validation Study Spermosens AB announced that development of the JUNO-Checked Generation 3 system is now complete. This innovative sensor system meets the performance standards necessary for a commercially viable product. The Company is preparing to initiate patient recruitment for a clinical validation study at the Reproductive Medicine Center (RMC) in Malmö. The development of JUNO-Checked Generation 3 has focused on the specific needs of clinics and laboratories. This system features significant key technical improvements, such as significantly shorter analysis times and a more robust sensor design to support high-volume clinical workflows. These enhancements are intended to reduce technical and operational risks for future partners and support integration into existing laboratory environment. The system is designed for compatibility with established laboratory platforms, enabling seamless adoption in clinical practice. The clinical validation study will be conducted at Reproductive Medicine Center (RMC) in Malmö and is designed to validate the performance of the new system in a clinical environment. Patient recruitment is expected to begin shortly. The study focuses on couples undergoing standard IVF due to unexplained infertility, where semen samples are classified as normal in routine testing. The aim is to demonstrate that JUNO-Checked provides additional diagnostic value by identifying sperm-related dysfunctions not detected by conventional methods. Completion of the study is expected by the end of the year. Successful validation is a key step toward registration and commercialization. In line with the Company strategy, Spermosens aims to bring JUNO-Checked to the market through license or co-development agreements. This approach is designed to reduce capital needs and improve the likelihood of a successful market introduction through established companies. JUNO-Checked addresses a global fertility market where improved functional testing is essential to support clinical decisions and improve treatment outcomes for millions of couples. Announcement • Apr 08
Spermosens AB (publ) to Report Q1, 2026 Results on May 07, 2026 Spermosens AB (publ) announced that they will report Q1, 2026 results on May 07, 2026 New Risk • Feb 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr11m free cash flow). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 10x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr24.7m market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Jan 13
Spermosens AB (publ) to Report Fiscal Year 2025 Results on Feb 11, 2026 Spermosens AB (publ) announced that they will report fiscal year 2025 results on Feb 11, 2026 Announcement • Dec 10
Spermosens AB Provides Update on Recent Progress and the Next Steps in Its Partner-Driven Commercialization Strategy for Juno-Checked Spermosens AB presents an update on recent progress and the next steps in its partner-driven commercialization strategy for JUNO-Checked. The Company completed a successful clinical study in June 2025, confirming the diagnostic value of JUNO-Checked and continues to build a strong foundation for a partner-led market introduction. Development of Generation 3, the intended commercial version, is progressing and dialogues with potential partners in Europe, the United States, Japan and Australia are advancing. Central to the Company's go-to-market strategy is the establishment of licensing and partnership structures that support regulatory activities, market adaptation and commercial rollout. This update contains forward-looking information about anticipated milestones, timelines and commercialization pathways. Such information reflects current expectations and is subject to risks and uncertainties, as outlined under "Forward-looking information" below. Product development and intellectual property: Spermosens has advanced several key areas: The completed clinical study in 2025 has demonstrated that JUNO-Checked provides relevant diagnostic information by assessing a critical biological step in fertilization not captured by conventional sperm analysis. Patent protection has been strengthened through approvals in multiple key markets. Development of the next-generation JUNO-Checked ("Generation 3") is progressing according to plan. H1 2026: Completion of Generation 3, H2 2026: Start clinical validation of Generation 3, H22026: Signing of partner and/or license agreements, H1 2027: Test and validation activities with partners, H2 2027: Regulatory filings and market preparation activities with partners, H1 2028: Commercial rollout through partners. Partner strategy and collaboration models: Spermosens commercialization strategy focuses on partnering with organizations already established in fertility care, diagnostics and patient-centric reproductive health services. Target partner categories include: Fertility technology companies developing tools to enhance diagnostics and workflows efficiency; Developers of automated laboratory systems used in IVF clinics and andrology laboratories; Fertility clinic groups and sperm banks with advanced in-house laboratory capabilities and interest in new diagnostic tools; Reproductive health platforms integrating diagnostics into patient-centric fertility services. These reflect the types of partners currently engaged in dialogue with Spermosens, including fertility-technology innovators, clinical networks and companies offering patient-centric fertility services. partnership structures: The Company's partnering approach is based on upfront and/or co-financing contributions, milestone payments and royalties on net sales. JUNO-Checked, as a functional sperm-egg binding assay, complements standard sperm analyses and addresses a growing need for more advanced and predictive male-fertility diagnostics. While the entire sperm-analysis market is not directly address for JUNO- checked, the introduction of new diagnostic possibilities may broaden clinical workflows over time. It is not possible to determine at this stage what proportion of the market JUNO-Checked may ultimately address, as this will depend on clinical adoption, regulatory pathways and partner-driven commercialization efforts. JUNO-Checking therefore introduces a novel functional approach to the assessment of male fertility. As such testing becomes available, new clinical use cases may emerge, including unexplained fertility, failed IVF cycles and advanced male-factor assessments, potentially increasing demand for more advanced and predictive diagnostics. Over time, this may extend the long-term opportunity for JUNO-Checking beyond current market definitions, as clinical practice evolves in response to improved diagnostic capabilities. Announcement • Nov 05
Spermosens AB Receives Patent Approval in Mexico Spermosens AB announced that the patent "Biosensor for male Infertility" has been granted in Mexico. The patent covers the company's unique method for measuring sperm binding to the egg, a critical biological interaction during fertilization that no existing test can evaluate. The patent granted in Mexico strengthens Spermosens' intellectual property portfolio, which already includes granted patents in key markets including Europe, United States of America, Canada, Japan, South Korea, Australia, South Africa, Hong Kong and Singapore. The protection covers both the method and system underlying the JUNO-Checked technology, providing long-term exclusivity for the company's approach to assessing critical sperm function. Announcement • Oct 23
Spermosens AB Receives Patent Approval in Canada Spermosens AB announced that the patent "Biosensor for male Infertility" has been granted in Canada. The patent covers the company's unique method for measuring sperm binding to the egg receptor JUNO - a critical biological interaction during fertilization that no existing test can evaluate. The patent granted in Canada further strengthens Spermosens' intellectual property portfolio, which already includes granted patents in key markets including Europe, United States of America, Japan, South Korea, Australia, South Africa, Hong Kong and Singapore. The protection covers both the method and system underlying the JUNO-Checked technology, providing long-term exclusivity for the company's approach to assessing critical sperm function. Announcement • Oct 14
Spermosens AB to Report Q3, 2025 Results on Nov 12, 2025 Spermosens AB announced that they will report Q3, 2025 results on Nov 12, 2025 Announcement • Aug 08
Spermosens AB Provides Status Update Following Successful Clinical Study Spermosens AB provided a status update following the successful completion of its clinical study with the second-generation JUNO-Checked system and the full subscription of TO5 warrants. These milestones strengthen the Company's position as it advances its diagnostic technology towards commercialization. The clinical study, conducted at the Reproductive Medicine Center in Malmo, demonstrated a statistically significant correlation between the JUNO Score -- which measures sperm binding to the JUNO receptor -- and fertilization rate in IVF. Notably, 22% of the men in the study had a low JUNO Score, despite having normal sperm parameters, highlighting the limitations of conventional sperm analysis. The findings, announced in June, underscore the unique diagnostic value of JUNO-Checked in assessing a critical step in fertilization that current methods cannot evaluate. A peer-reviewed article detailing the results is in preparation. In parallel, the Company's T05 warrants were fully subscribed during the June subscription period which strengthen Spermosens' financial position and enable continued technology optimization and strategic business development. With positive clinical results and an improved financial foundation, Spermosens is accelerating its efforts to secure strategic partners in Europe, the United States and Japan. Following the announcement of the clinical results, the Company has seen growing interest in its technology and is actively engaged in discussions with several potential partners across key markets. At the same time, Spermosens has initiated optimization of the JUNO-Checked systems to meet commercial demands. This work aims to bring the system closer to a commercial launch in collaboration with established partners. The goal is to deliver accurate and efficient measurement of sperm cells' ability to bind to the egg with higher throughput, faster analysis time and adapted for routine laboratory practice. The ongoing optimization is expected to result in a diagnostic tool with the potential to transform how sperm quality is assessed. JUNO-Checked may enable more effective IVF treatments, improved selection of sperm donors, and potentially a new way to evaluate when a man is most fertile. Next major milestones in the Company's development include finalization of the third-generation JUNO- checked system, clinical validation of this next version, and the signing of partnership agreements to enable commercialization. Announcement • Jul 22
Spermosens AB to Report Q2, 2025 Results on Aug 20, 2025 Spermosens AB announced that they will report Q2, 2025 results on Aug 20, 2025 New Risk • Jun 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (378% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr12.2m market cap, or US$1.28m). Announcement • Jun 11
Spermosens AB Concludes Clinical Study with Statistically Significant Results Supporting the Diagnostic Value of JUNO-Checked Spermosens AB announces positive topline results from its clinical study conducted at the Reproductive Medicine Center (RMC) in Malmö. The study was designed to validate the diagnostic value of the Company's patented JUNO-Checked system and has now reached a successful conclusion. The results demonstrate a statistically significant correlation between the JUNO Score, a measurement of sperm binding to the JUNO receptor, and fertilization rate in IVF. Key results: A total of 83 couples were recruited, and 66 semen samples were analyzed. Of these, 53 cases met all inclusion criteria and were included in the final statistical analysis. All participating couples were undergoing standard IVF due to unexplained infertility, with semen samples classified as "nothing abnormal detected" (NAD) in standard testing. The median age was 34 years for both women (max 40) and men (max 50), representing a typical IVF population. The study's primary finding is a statistically significant positive correlation between the JUNO Score and fertilization rate, defined as the percentage of mature oocytes (MII) that developed into two-pronuclear (2PN) zygotes. This means that samples with higher JUNO Scores - reflecting stronger sperm binding to the JUNO receptor - were associated with higher fertilization rates. In contrast, fertilization rates were low in cases with low or undetectable JUNO binding. The results demonstrate that JUNO-Checked offers a unique diagnostic value by functionally assessing sperm binding capacity - a critical step in fertilization that current methods cannot detect. Clinical and strategic implications; Currently, there is no diagnostic tool available in clinical practice to assess the functional ability of sperm to bind to the egg. For couples where standard tests yield normal results but fertilization still fails, JUNO-Checked may offer a long-awaited explanation, enabling more individualized treatment strategies and potentially improving IVF outcomes. With the clinical study now successfully completed, Spermosens will focus on optimizing the JUNO-Checked system to meet commercial requirements. A bridging study is planned using the next-generation, commercially adapted version of the system to support regulatory approval and market entry. Preparation of a peer-reviewed article will begin, presenting the full analysis of the clinical study. In parallel, Spermosens is engaged in active discussions with potential commercial partners in Europe, the US, and Japan. The positive clinical findings significantly enhance the Company's position in these ongoing dialogues. The newly formed partnership with Scalania AG is expected to strengthen regulatory and market activities in Europe, while the collaboration with ScanMed Partners drives business development in the US. In Japan, discussions are advancing with a leading company that holds a strategic interest in assisted reproductive technologies. New Risk • May 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 31x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr11.1m market cap, or US$1.15m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Announcement • May 02
Spermosens AB Provides Update on Clinical Progress, Partner Discussions and Financing Spermosens AB provided an update on its ongoing clinical study, commercial discussions and financing. The clinical study at the Reproductive Medicine Center (RMC) in Malmo is progressing well, with 68 couples successfully recruited to date and JUNO binding analysis completed in 51 cases. The Company remains on track to achieve its clinical objectives and is confident it will complete the study by the end of 2025, or potentially earlier. Interim results to date continue to demonstrate a correlation between JUNO binding and fertilization outcomes, with the next interim analysis expected this summer. These findings further support the potential of JUNO-Checked as a diagnostic tool in assisted reproductive treatments. In parallel, Spermosens is in active dialogue with potential commercial partners in Europe, the US and Japan, who are closely following the clinical study. The Company has further strengthened its US business development through the collaboration with ScanMed Partners and expanded its European activities through the partnership with Scalania AG. In Japan, Spermosens continues a positive dialogue with an established company following the signing of a memorandum of understanding in late 2024, aiming to conclude a license agreement for the Japanese market based on positive outcome from the ongoing clinical study. As previously communicated, Spermosens recently secured a strategic investment from European and US investors, providing the financial foundation necessary to execute on its strategy. This includes completing the ongoing clinical study, advancing the JUNO-Checked technology and continuing the pursuit of commercial partnerships. Announcement • Apr 08
Spermosens AB to Report Q1, 2025 Results on May 07, 2025 Spermosens AB announced that they will report Q1, 2025 results on May 07, 2025 Announcement • Apr 02
Spermosens Reports Positive Second Interim Results from Clinical Study Spermosens AB announced the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company's patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first interim analysis released in December 2024. Specifically, the results continue to demonstrate correlation between the JUNO binding and fertility outcomes. To date, the study has successfully recruited 52 couples, with JUNO binding analysis completed in 37 of these cases. The interim results show that a higher JUNO binding, reflecting the sperm cells' ability to bind to the egg, is positively correlated with better fertilization and pregnancy outcomes. In contrast, cases with very low or absent JUNO binding do not result in fertilization, further reinforcing the clinical relevance of the JUNO-Checked technology as a diagnostic tool in assisted reproductive treatments. These findings provide growing evidence that the JUNO-Checked system can help identify sperm related factors in unexplained infertility. Particularly in couples with no identifiable reproductive issues, where standard semen parameters are within normal ranges, and yet fertilization and pregnancy repeatedly fail. The clinical study continues to generate valuable insights into the role of sperm binding capacity in assisted reproductive treatments. The latest results further strengthen the predictive value of JUNO-Checked, reinforcing its potential as a key tool for fertility diagnostics in IVF clinics and sperm banks. The ambition is to complete the study in 2025, delivering solid clinical evidence that supports the diagnostic value of the JUNO-Checked technology and lay the ground for securing licensing agreements with established partners in the ART market. Announcement • Mar 31
Spermosens Appoints Jaime Castillo-León as Chief Technology Officer to Drive Innovation and Technology Development, Effective April 1, 2025 Spermosens AB (publ) announced the appointment of Dr. Jaime Castillo-León as Chief Technology Officer (CTO) as part of the plan to advance JUNO-Checked technology and establish licensing agreements with leading players in the assisted reproductive technology (ART) market. Strengthening the team's technology expertise is a key step in executing the Company's recently announced plan to achieve positive cash flow from the second half of 2026. Dr. Castillo-León, an expert in biosensors, microfluidics and lab-on-a-chip technologies, has joined Spermosens as CTO from April 1st. With over two decades of experience in biomedical engineering and diagnostic systems, Dr. Castillo-León brings the expertise needed to further develop JUNO-Checked, ensuring commercial viability and scalability. He holds a Ph.D. in electrochemical biosensors for biomedical applications from Lund University and has previously served as a Senior Researcher at DTU, where he contributed to multiple high-impact projects in the field of biomedical diagnostics. As CTO, Dr. Castillo-León will lead Spermosens' technology maturation efforts, focusing on optimizing JUNO-Checked to improve accuracy, efficiency and integration with commercially available instruments. This work, in collaboration with partners such as FlexMedical Solutions and PalmSens, is a critical part of the Company's strategy to secure licensing agreements with upfront payments, milestones and royalties on net sales. The appointment of Dr. Castillo-León follows the recent strategic investment of SEK 10.8 million, which strengthened the Company's financial foundation to accelerate product development and business development efforts. With a reinforced leadership team, Spermosens remains focused on executing its plan to achieve positive cash flow and deliver innovative solutions to the ART market. Announcement • Mar 16
Spermosens AB announced that it has received SEK 10.8 million in funding On March 14, 2025, Spermosens AB closed the transaction. Announcement • Mar 06
Spermosens AB announced that it expects to receive SEK 10.8 million in funding Spermosens AB announces to issue 1,350,000,000 shares at a price of SEK 0.0080 per share for gross proceeds of SEK 10.8 million on March 4, 2025. Announcement • Jan 15
Spermosens Announces Relocation to A Smaller Office At Medicon Village Spermosens AB announced that it is relocating to a smaller office within Medicon Village, The Spark. While the Company retains its existing address, this move is part of its continued commitment to operational efficiency and cost-consciousness. The decision to move to a more space-efficient office reflects Spermosens' strategic focus on advancing its clinical study and ongoing discussions with potential partners. By optimizing resources, the Company ensures that its efforts remain directed toward achieving key milestones and creating long-term value for shareholders. Spermosens remains fully operational at Medicon Village, The Spark, a leading hub for life science innovation, providing access to collaboration opportunities and resources to support the Company's growth and development. Recent Insider Transactions • Jan 01
Part Time Chief Financial Officer recently sold kr50k worth of stock On the 23rd of December, Ulrik Nilsson sold around 4m shares on-market at roughly kr0.011 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ulrik's only on-market trade for the last 12 months. Announcement • Dec 19
Spermosens AB Announces Positive Results from Ongoing Clinical Study Spermosens AB announced the first interim results from its ongoing clinical study aimed at validating the diagnostic value of the patented JUNO-Checked system. The study is progressing as planned, and the first results are now being presented according to schedule. The first interim results from the clinical study show a positive correlation between higher JUNO scores, which measure the sperm cells' binding capacity to the egg, and increased fertilization rates and pregnancy outcomes following IVF treatments. JUNO-Checked, the first-ever method to measure this binding capacity, represents a groundbreaking advancement in male fertility diagnostics. The results mark a significant step in demonstrating the potential of this innovative technology to enhance fertility care. The study, conducted at the Reproductive Medicine Center (RMC) in Malmo, has successfully recruited 25 couples, with clinical data collected from 13 cases. The interim analysis reveals several key findings that support the clinical relevance of the JUNO-Checked systems. Higher JUNO scores are associated with improved fertilization rates. Positive correlation was also observed between JUNO scores and pregnancy outcomes, with higher scores relating with an increased likelihood of successful pregnancies following IVF treatments. These findings indicate that the JUNO-Checking technology could serve as a valuable predictive diagnostic tool for enhancing fertility treatment. In addition to its correlation with fertilization and pregnancy outcomes, the JUNO score also appears to be linked to embryo quality. High JUNO binding affinity is associated with a greater rate of high-quality embryos, emphasizing the role of sperm-egg binding capacity in determining reproductive success. The study explores the potential impact of age on fertility outcomes. For women, the interim results show that women under 35 years demonstrate a higher level of binding between IZUMO and JUNO proteins. This finding aligns with existing knowledge that women over 35 typically exhibit lower egg and embryo quality. The data suggest an age-related factor in women that impacts the binding efficiency of IZUMO on sperm to JUNO on the egg membrane. They further validate the potential of Spermosens' JUNO-Checked technology to improve fertility diagnostics in IVF clinics and enhance donor selection for sperm banks. This aligns with the Company's vision of addressing critical gaps in the global assisted reproductive technology (ART) market, which is estimated to be worth USD 25 billion and growing at an annual rate of 6%. The ongoing study will continue to recruit additional patients, with further interim analyses planned in 2025. These milestones are expected to strengthen Spermosens' position in discussions with potential partners in Europe, the United States and Japan, paving the way for broader adoption of JUNO-Checked Technology. Announcement • Dec 11
Spermosens AB to Report Fiscal Year 2024 Results on Feb 12, 2025 Spermosens AB announced that they will report fiscal year 2024 results on Feb 12, 2025 Announcement • Nov 19
Spermosens AB Provides Update on Clinical Study Progress Spermosens AB provided an update on its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö. This study, which evaluates the diagnostic relevance of the second-generation JUNO-Checked technology, is a significant step toward advancing personalized IVF treatments and supporting sperm banks in identifying the best possible donors. The second-generation JUNO-Checked offers improved performance and a shorter readout time, enhancing the accuracy and efficiency of the analysis. Now in its sixth week, the study has received strong participation from couples eager to take part. Their involvement has enabled the Company to measure the binding potential of several donor samples using the second-generation JUNO-Checked system. The focus is on assessing the binding capacity of sperm cells to the egg, a critical factor in male fertility diagnostics. In close collaboration with RMC, the data is being correlated with fertilization outcomes to better understand the relationship between sperm binding capacity and successful fertilization. This will ultimately lead to a valuable diagnostic tool for clinicians to personalize treatment and for sperm banks to select high-quality donors. This study is expected to provide key insights into how JUNO-Checked can personalize fertility treatments by identifying sperm with optimal binding potential, thus improving success rates. Furthermore, JUNO-Checked could help sperm banks qualify donors with the best fertility profiles, enhancing their service quality and outcomes for recipients. These developments will not only position JUNO-Checked as an essential tool in reproductive medicine but also make it attractive to potential partners and future customers seeking advanced, reliable solutions in male infertility diagnostics. Spermosens remains focused on recruiting additional couples and delivering interim results before the end of 2024. These preliminary results will indicate the potential of JUNO-Checked to address key challenges in male infertility, positioning the technology as a valuable asset for both fertility treatment clinics and sperm banks. About JUNO-Checked: The second-generation JUNO-Checked is designed to address critical gaps in male infertility diagnostics by assessing the sperm's capacity to bind to the egg. With improved performance and a shorter readout time, this approach provides deeper insights into sperm function, supports personalized fertility treatments, and enhances the donor selection process for sperm banks, helping couples and institutions achieve better outcomes. The continued development of JUNO-Checked also makes it an increasingly appealing solution for potential partners and future customers in the reproductive medicine and fertility sectors. Announcement • Nov 05
Spermosens AB Announces Advancements in Second-Generation JUNO-Checked System Spermosens AB provided share additional information on the enhanced capabilities of its second-generation JUNO-Checked system, a significant advancement in male fertility diagnostics. JUNO-Checked is the first device that enables clinicians and researchers to measure sperm binding capacity - a critical parameter that complements current analyses in IVF clinics and provides deeper insights into male fertility. The second-generation JUNO-Checked system builds on the strengths of the initial platform, introducing enhancements in sensitivity, accuracy and data processing speed. These improvements are tailored to increase the device's utility in clinical settings and strengthen its role in the ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö. Key achievements of the second-generation checked system: Enhanced Sensitivity and Accuracy: The upgraded sensor technology in the second generation delivers more precise measurements of sperm binding ability, a capability unique to JUNO-Checked. This advancement reduces noise and variability, which is crucial for identifying subtle variations that may be linked to IVF success. Faster data processing: The system's advanced biosensors enable more rapid and robust data analysis, allowing for complex statistical evaluations. This improvement is particularly valuable in clinical use, where multiple parameters are analyzed together to establish JUNO-Checked's diagnostic value. Ease of use: The new JUNO-Checked system features a more user-friendly design, making it easier for lab teams to operate and ensuring data collection remains consistent across samples. This enhanced usability is especially advantageous for laboratories handling large sample volumes. Increased sample throughput: The upgraded JUNO-Checked system also supports higher sample throughput, allowing for faster processing of more samples. This capability is particularly beneficial for fertility clinics looking to streamline operations. These technical advancements bring Spermosens closer to fulfilling its mission of addressing critical gaps in male fertility diagnostics, offering specialists innovative tools that support more effective fertility treatments. Announcement • Oct 30
Spermosens AB to Report Q3, 2024 Results on Nov 28, 2024 Spermosens AB announced that they will report Q3, 2024 results on Nov 28, 2024 Announcement • Oct 16
Spermosens AB (publ) Receives Notice of Allowance for Broad US Patent Covering JUNO-Checked Technology Spermosens AB (publ) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of claims compared to Spermosens' first US patent. This patent includes claims for a biosensor utilizing the JUNO protein immobilized on a variety of substrates, significantly expanding the scope beyond the previously patented dish, microbead, or electrode substrates. The biosensor is designed to detect or quantify sperm function, offering novel insights into male fertility diagnostics.Upon grant, Spermosens will hold two US patents, further strengthening its intellectual property portfolio and positioning the Company for future partnerships in the assisted reproductive technology (ART) sector. These patents represent a key milestone in Spermosens' mission to enhance male fertility diagnostics and deliver solutions for IVF clinics and other stakeholders in the reproductive health industry. The patent is expected to be formally granted early 2025. Spermosens also holds patent protection in other key markets, including Europe and Japan. Announcement • Jun 14
Spermosens AB to Report First Half, 2024 Results on Jul 12, 2024 Spermosens AB announced that they will report first half, 2024 results on Jul 12, 2024 New Risk • May 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 47% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr39.3m market cap, or US$3.69m). Announcement • May 01
Spermosens AB to Report Q1, 2024 Results on May 30, 2024 Spermosens AB announced that they will report Q1, 2024 results on May 30, 2024 Announcement • Apr 11
Spermosens AB, Annual General Meeting, May 10, 2024 Spermosens AB, Annual General Meeting, May 10, 2024. New Risk • Feb 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (240% increase in shares outstanding). Market cap is less than US$10m (kr17.2m market cap, or US$1.64m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.1m). Announcement • Jan 11
Spermosens AB to Report Fiscal Year 2023 Results on Feb 09, 2024 Spermosens AB announced that they will report fiscal year 2023 results on Feb 09, 2024 Reported Earnings • Oct 18
Third quarter 2023 earnings released: kr0.085 loss per share (vs kr0.27 loss in 3Q 2022) Third quarter 2023 results: kr0.085 loss per share. Net loss: kr3.51m (loss widened 9.3% from 3Q 2022). Announcement • Sep 14
Spermosens AB to Report Q3, 2023 Results on Oct 13, 2023 Spermosens AB announced that they will report Q3, 2023 results on Oct 13, 2023 New Risk • Aug 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (240% increase in shares outstanding). Market cap is less than US$10m (kr30.9m market cap, or US$2.83m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m). Announcement • Jun 15
Spermosens AB to Report Q2, 2023 Results on Jul 14, 2023 Spermosens AB announced that they will report Q2, 2023 results on Jul 14, 2023 Reported Earnings • Apr 21
First quarter 2023 earnings released: kr0.12 loss per share (vs kr0.24 loss in 1Q 2022) First quarter 2023 results: kr0.12 loss per share. Net loss: kr3.28m (loss widened 29% from 1Q 2022). Reported Earnings • Feb 26
Full year 2022 earnings released: kr1.10 loss per share (vs kr0.73 loss in FY 2021) Full year 2022 results: kr1.10 loss per share (further deteriorated from kr0.73 loss in FY 2021). Revenue: kr11.7m (down 6.6% from FY 2021). Net loss: kr12.6m (loss widened 97% from FY 2021). Announcement • Jan 25
Spermosens AB has completed a Composite Units Offering in the amount of SEK 24.425427 million. Spermosens AB has completed a Composite Units Offering in the amount of SEK 24.425427 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 29,077,889
Price\Range: SEK 0.84
Transaction Features: Rights Offering Announcement • Jan 10
Spermosens AB to Report Fiscal Year 2022 Results on Feb 08, 2023 Spermosens AB announced that they will report fiscal year 2022 results on Feb 08, 2023 Board Change • Nov 16
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. Chief Scientific Officer & Director Kushagr Punyani is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 17
Third quarter 2022 earnings released: kr0.27 loss per share (vs kr0.19 loss in 3Q 2021) Third quarter 2022 results: kr0.27 loss per share (further deteriorated from kr0.19 loss in 3Q 2021). Revenue: kr2.08m (down 32% from 3Q 2021). Net loss: kr3.21m (loss widened 64% from 3Q 2021). Reported Earnings • Jul 18
Second quarter 2022 earnings released: kr0.34 loss per share (vs kr0.25 loss in 2Q 2021) Second quarter 2022 results: kr0.34 loss per share (down from kr0.25 loss in 2Q 2021). Revenue: kr3.38m (up 3.1% from 2Q 2021). Net loss: kr3.75m (loss widened 70% from 2Q 2021). Board Change • Apr 27
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. Chief Scientific Officer & Director Kushagr Punyani is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 16
First quarter 2022 earnings released: kr0.24 loss per share (vs kr0.17 loss in 1Q 2021) First quarter 2022 results: kr0.24 loss per share (down from kr0.17 loss in 1Q 2021). Revenue: kr3.96m (up 155% from 1Q 2021). Net loss: kr2.54m (loss widened 185% from 1Q 2021). Reported Earnings • Feb 12
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr0.73 loss per share (down from kr0.39 loss in FY 2020). Revenue: kr13.1m (up 459% from FY 2020). Net loss: kr6.42m (loss widened 214% from FY 2020). Revenue was in line with analyst estimates. Announcement • Jul 15
European Patent Office Grants Patent to Spermosens AB Spermosens AB announced that the European Patent Office (EPO) has granted the patent EP 3768 825, which protects the company's biosensor and its use for in vitro fertilization. The formal grant follows the previous "Intention to Grant"-notification communicated April 16th 2021. Based on EPO:s grant of the patent with number EP 3 768 825, a European protection exists until 2039 and encompasses the company's biosensor product and its use for, e.g. detecting and quantifying sperm binding function, diagnosis of male infertility, and selection of sperms suitable for In Vitro Fertilization (IVF) purposes. The formal date of grant of the European patent is August 11th 2021. Spermosens has corresponding patent applications pending in Australia, Brazil, Canada, China, Eurasia (including Russia), Hong Kong, Israel, India, Japan, Mexico, New Zealand, Singapore, South Korea, South Africa and the USA. 